Migraine Report Migraine-Report | Page 27

Project Progress Report
Table - 8: Changes in VAS and MIDAS after receiving ATP
VAS
Sr. No. CRF No. Age Sex
No. of headache days in
last 90 days
MIDAS
Pre-ATP Post-ATP Pre-ATP Post-ATP
Pre-ATP Post-ATP
1 001 28 F 8 2 20 4 90 4
2 003 32 F 8 3 55 10 90 15
3 004 27 F 8 0 50 0 60 5
4 005 24 F 8 3 22 3 90 5
5 006 41 F 9 2 30 7 36 6
6 008 38 F 7 2 22 5 30 5
7 009 46 M 7 LTF 47 LTF 90 LTF
8 010 36 F 8 3 53 16 45 10
9 011 47 F 9 2 40 12 90 7
10 015 41 F 8 0 28 2 36 6
11 016 51 M 9 2 28 3 60 10
12 024 50 F 8 1 41 12 66 12
13 029 28 M 7 0 57 9 33 15
14 031 42 F 8 LTF 39 LTF 39 LTF
15 036 22 M 8 LTF 27 LTF 43 LTF
16 039 18 M 7 LTF 41 LTF 36 LTF
17 047 30 F 9 3 38 10 90 7
18 048 26 F 9 LTF 48 LTF 39 LTF
19 050 27 M 8 LTF 35 LTF 30 LTF
20 053 40 F 9 3 52 7 65 5
21 055 30 F 9 3 47 6 60 5
22 058 39 F 8 3 37 5 90 10
23 059 36 F 7 2 52 10 45 4
24 060 26 F 9 3 39 10 36 5
Randomized controlled clinical trial to evaluate prophylactic
27 properties of Ayu rv ed ic Treatment Protocol in
refractory and chronic migraine patients